Kastelein Jacob Pieter Johannes's most recent trade in NewAmsterdam Pharma Company NV was a trade of 50,000 Ordinary Shares done at an average price of $24.3 . Disclosure was reported to the exchange on Aug. 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.29 per share. | 21 Aug 2025 | 50,000 | 119,302 | - | 24.3 | 1,214,500 | Ordinary Shares |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.08 per share. | 21 Aug 2025 | 42,342 | 76,960 | - | 25.1 | 1,061,937 | Ordinary Shares |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.49 per share. | 21 Aug 2025 | 7,658 | 69,302 | - | 25.5 | 195,202 | Ordinary Shares |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 45,481 | 79,481 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 45,481 | 45,481 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 45,481 | 0 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 19,302 | 169,302 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2025 | 150,000 | 820,229 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2025 | 150,000 | 150,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 34,000 | 34,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 200,000 | 200,000 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 201,673 | 970,229 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 201,673 | 201,673 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 26 Mar 2024 | 190,476 | 0 | - | 21.5 | 4,095,234 | Ordinary Shares |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.72 per share. | 26 Mar 2024 | 11,197 | 190,476 | - | 22.7 | 254,396 | Ordinary Shares |
| NewAmsterdam Pharma Compan... | Kastelein Jacob Pieter Johannes | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 500,000 | 500,000 | - | - | Option (right to buy) |